EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R Spigel iD, Afshin Dowlati iD, Yuanbin Chen iD, Alejandro Navarro iD, James Chih-Hsin Yang iD, Goran Stojanovic, Maria Jove iD, Patricia Rich, Zoran G Andric, Yi-Long Wu iD, Charles M Rudin iD, Huanyu Chen und 6 weitere

Journal of Clinical Oncology · 01.07.2024 · 42 (19) · 2317-2326

DOI: 10.1200/jco.23.02110 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2024. Verfasst von David R Spigel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN. Hauptthemen laut MEDLINE: Topotecan, Irinotecan, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m 2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m 2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) and objective response rate (ORR). RESULTS Among 461 randomly assigned patients, 229 received liposomal irinotecan and 232 received topotecan. The median follow-up was 18.4 months. The median OS was 7.9 months with liposomal irinotecan versus 8.3 months with topotecan (hazard ratio [HR], 1.11 [95% CI, 0.90 to 1.37]; P = .31). The median PFS per blinded independent central review (BICR) was 4.0 months with liposomal irinotecan and 3.3 months with topotecan (HR, 0.96 [95% CI, 0.77 to 1.20]; nominal P = .71); ORR per BICR was 44.1% (95% CI, 37.6 to 50.8) and 21.6% (16.4 to 27.4), respectively. Overall, 42.0% and 83.4% of patients receiving liposomal irinotecan and topotecan, respectively, experienced grade ≥3 related treatment-emergent adverse events (TEAEs). The most common grade ≥3 related TEAEs were diarrhea (13.7%), neutropenia (8.0%), and decreased neutrophil count (4.4%) with liposomal irinotecan and neutropenia (51.6%), anemia (30.9%), and leukopenia (29.1%) with topotecan. CONCLUSION Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TopotecanIrinotecanSmall Cell Lung CarcinomaLung NeoplasmsLiposomesNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overProgression-Free SurvivalTopoisomerase I Inhibitors

Substanzen

TopotecanIrinotecanLiposomesTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
  • University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH.
  • Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI.
  • Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
  • Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.

ORCID-Profile: David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Maria Jove, Yi-Long Wu, Charles M Rudin, Luis Paz-Ares, Paul A Bunn

Förderung

  • NCI NIH HHS

Zitieren

APA

Spigel, D. R., Dowlati, A., Chen, Y., Navarro, A., Yang, J. C., Stojanovic, G., Jove, M., Rich, P., Andric, Z. G., Wu, Y. L., Rudin, C. M., Chen, H., Zhang, L., Yeung, S., Benzaghou, F., Paz-Ares, L., Bunn, P. A., & RESILIENT Trial Investigators (2024). RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of Clinical Oncology, 42(19), 2317-2326. https://doi.org/10.1200/jco.23.02110

Vancouver

Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, et al. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. Journal of Clinical Oncology. 2024;42(19):2317-2326. doi:10.1200/jco.23.02110

BibTeX
@article{Spigel2024,
  author = {Spigel, David R and Dowlati, Afshin and Chen, Yuanbin and Navarro, Alejandro and Yang, James Chih-Hsin and Stojanovic, Goran and Jove, Maria and Rich, Patricia and Andric, Zoran G and Wu, Yi-Long and Rudin, Charles M and Chen, Huanyu and Zhang, Li and Yeung, Stanley and Benzaghou, Fawzi and Paz-Ares, Luis and Bunn, Paul A and RESILIENT Trial Investigators, RESILIENT Trial Investigators},
  title = {RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {19},
  pages = {2317--2326},
  doi = {10.1200/jco.23.02110}
}
Kostenlos starten →